Germany
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Corden Pharma International GmbH.
5 March 2025 – Basel, Switzerland >
Following its 16 July 2024 announcement, CordenPharma is pleased to share significant progress on its growth initiatives with a >€1 billion strategic investment in peptide development and manufacturing. The company’s ambitious expansion plans are set to propel its Peptide Platform business beyond the €1 billion sales milestone by 2028, reinforcing CordenPharma’s position as a market leader in integrated supply of small to large-scale services from APIs to Drug Products, for both Injectable and Oral Peptides.
As part of this strategy, CordenPharma has finalized plans to establish a state-of-the-art peptide manufacturing facility in Switzerland located at Getec Park in Muttenz, just 8 km outside Basel – a major biotech and pharma hub within Europe.
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.
CordenPharma, a global CDMO leader in the manufacture of Drug Substances (APIs) for complex modalities (such as peptides, GalNAc, lipids, etc.), Lipid NanoParticles (LNPs) containing xRNA / xDNA, and injectable Drug Products, and Certest, a Spanish company focused on the development of new products with special emphasis in Drug Delivery with LNPs and API synthesis, have signed a partnership agreement.
This is the News section of the company profile page for Corden Pharma International GmbH on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
